论文部分内容阅读
Ruboxistaurin甲磺酸水合物(LY 3335 31)是由礼莱公司开发的一种口服蛋白激酶C抑制剂,目前正处Ⅲ期临床开发阶段,用于治疗糖尿病微血管并发症,如糖尿病视网膜病和黄斑水肿。本品CAS :2 0 2 2 6 0 2 1 7化学结构式: 药理作用 最近一项旨在考察ruboxistaurin对糖尿病及非糖
Ruboxistaurin methanesulfonic acid hydrate (LY 3335 31), an oral protein kinase C inhibitor developed by Lilly, is currently in Phase III clinical development for the treatment of diabetic microvascular complications such as diabetic retinopathy and macular degeneration Edema. This product CAS: 2 0 2 2 6 0 2 1 7 Chemical Structure: Pharmacological effects A recent study aims to investigate ruboxistaurin on diabetes and non-sugar